Androgen Receptor Gene Polymorphisms and Increased Risk of Urologic Measures of Benign Prostatic Hyperplasia

American Journal of Epidemiology

Volumn 159, Issue 3, 2004, Pages 269-276

  Roberts, Rosebud O ^a   Bergstralh, Erik J ^a   Cunningham, Julie M ^a   Hebbring, Scott J ^a   Thibodeau, Stephen N ^a   Lieber, Michael M ^a   Jacobsen, Steven J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Androgen; Cohort studies; Polymorphism (genetics); Prostate; Prostatic hyperplasia; Receptors; Risk factors; Signs and symptoms; Urinary retention

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; REPETITIVE DNA;

HEALTH RISK;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CAG REPEAT; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DISEASE SEVERITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GGN REPEAT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; RANDOMIZATION; RECEPTOR GENE; SYMPTOMATOLOGY; TRINUCLEOTIDE REPEAT; UNITED STATES; URETHRA DISEASE; URINE FLOW RATE; UROLOGIC EXAMINATION;

COHORT STUDIES; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; PROSTATIC HYPERPLASIA; RANDOM ALLOCATION; RECEPTORS, ANDROGEN; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 0942290567     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwh042     Document Type: Article

References (32)

1. Tut TG, Ghadessy FJ, Trifiro MA, et al. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 1997;82:3777-82.
2. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181-6.
3. Choong CS, Kemppainen JA, Zhou ZX, et al. Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol Endocrinol 1996;10:1527-35.
4. Gao T, Marcelli M, McPhaul MJ. Transcriptional activation and transient expression of the human androgen receptor. J Steroid Biochem Mol Biol 1996;59:9-20.
5. Stanford JL, Just JJ, Gibbs M, et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997;57:1194-8.
6. Hakimi JM, Schoenberg MP, Rondinelli RH, et al. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 1997;3:1599-608.
7. Platz EA, Giovannucci E, Dahl DM, et al. The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:379-84.
8. Sleddens HF, Oostra BA, Brinkmann AO, et al. Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum Mol Genet 1993;2:493.
9. Edwards SM, Badzioch MD, Minter R, et al. Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer 1999;84:458-65.
10. Mitsumori K, Terai A, Oka H, et al. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. Prostate 1999;41:253-7.
11. Giovannucci E, Platz EA, Stampfer MJ, et al. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology 1999;53:121-5.
12. Giovannucci E, Stampfer MJ, Chan A, et al. CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. Prostate 1999;39:130-4.
13. Schatzl G, Madersbacher S, Gsur A, et al. Association of polymorphisms within androgen receptor, 5a-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate 2002;52:130-8.
14. Bousema JT, Bussemakers MJG, Van Houwelingen KP, et al. Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol 2000;37:234-8.
15. El Din KE, Koch WFRM, De Wildt MJAM, et al. Reliability of the international prostate symptom score in the assessment of patients with lower urinary tract symptoms and/or benign prostatic hyperplasia. J Urol 1996;155:1959-64.
16. O'Connor RC, Bales GT, Avila D, et al. Variability of the international prostate symptom score in men with lower urinary tract symptoms. Scand J Urol Nephrol 2003;37:35-7.
17. Matzkin H, Van Der Zwaag R, Chen Y, et al. How reliable is a single measurement of urinary flow in the diagnosis of obstruction in benign prostatic hyperplasia? Br J Urol 1993;72:181-6.
18. Reynard JM, Peters TJ, Lim C, et al. The value of multiple free-flow studies in men with lower urinary tract symptoms. Br J Urol 1996;77:813-18.
19. Jacobsen SJ, Guess HA, Panser L, et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms: The Olmsted County Study of Urinary Symptoms and Health Status among Men. Arch Fam Med 1993;2:729-35.
20. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270:860-4.
21. Oesterling JE, Jacobsen SJ, Klee GG, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090-5.
22. Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community-dwelling men. J Urol 1996;155:595-600.
23. Barry MJ, Fowler FJJ, O'Leary MP, et al. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Urol 1992;148:1549-57.
24. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol 1991;145:984-7.
25. La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991;352:77-9.
26. Irvine RA, Yu MC, Ross RK, et al. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995;55:1937-40.
27. Hsing AW, Gao YT, Wu G, et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 2000;60:5111-16.
28. Shibata A, Stamey TA, McNeal JE, et al. Genetic polymorphisms in the androgen receptor and type II 5a-reductase genes in prostate enlargement. J Urol 2001;166:1560-4.
29. Mononen N, Ikonen T, Autio V, et al. Androgen receptor CAG polymorphism and prostate cancer risk. Hum Genet 2002;111:166-71.
30. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med 1995;155:477-81.
31. Panser LA, Chute CG, Guess HA, et al. The natural history of prostatism: the effects of non-response bias. Int J Epidemiol 1994;23:1198-205.
32. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-7.